These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Cady RK; Banks J; Jones BA; Campbell J Curr Med Res Opin; 2009 Nov; 25(11):2711-21. PubMed ID: 19778164 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Amanzio M; Corazzini LL; Vase L; Benedetti F Pain; 2009 Dec; 146(3):261-269. PubMed ID: 19781854 [TBL] [Abstract][Full Text] [Related]
6. [Acute migraine medications and evolution from episodic to chronic migraine]. Haag G MMW Fortschr Med; 2009 Feb; 151(6):41, 43. PubMed ID: 19432251 [No Abstract] [Full Text] [Related]
8. [Treatment guidelines for acute migraine attacks]. Treatment Guideline Subcommittee of Taiwan Headache Society Acta Neurol Taiwan; 2007 Dec; 16(4):251-68. PubMed ID: 18220021 [TBL] [Abstract][Full Text] [Related]
9. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Schulman EA; Lake AE; Goadsby PJ; Peterlin BL; Siegel SE; Markley HG; Lipton RB Headache; 2008 Jun; 48(6):778-82. PubMed ID: 18484982 [TBL] [Abstract][Full Text] [Related]
10. Almotriptan in triptan-naïve patients: new evidence of benefits. Pascual J Cephalalgia; 2008 Sep; 28 Suppl 2():14-20. PubMed ID: 18715328 [TBL] [Abstract][Full Text] [Related]
11. Drug safety in acute migraine treatment. Tajti J; Majláth Z; Szok D; Csáti A; Vécsei L Expert Opin Drug Saf; 2015 Jun; 14(6):891-909. PubMed ID: 25773005 [TBL] [Abstract][Full Text] [Related]
12. [Treatment guidelines for preventive treatment of migraine]. Treatment Guideline Subcommittee of the Taiwan Headache Society Acta Neurol Taiwan; 2008 Jun; 17(2):132-48. PubMed ID: 18686655 [TBL] [Abstract][Full Text] [Related]
13. Migraine treatment. Young WB; Silberstein SD; Dayno JM Semin Neurol; 1997; 17(4):325-33. PubMed ID: 9474712 [TBL] [Abstract][Full Text] [Related]
14. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Amanzio M Recent Pat CNS Drug Discov; 2011 Jan; 6(1):41-7. PubMed ID: 21118096 [TBL] [Abstract][Full Text] [Related]
15. Overview of diagnosis and treatment of migraine. Silberstein SD; Lipton RB Neurology; 1994 Oct; 44(10 Suppl 7):S6-16. PubMed ID: 7969947 [TBL] [Abstract][Full Text] [Related]
16. Triptan migraine treatments and antidepressants: risk of serotonin syndrome. Wooltorton E CMAJ; 2006 Oct; 175(8):874. PubMed ID: 16988028 [No Abstract] [Full Text] [Related]
17. Acute drug treatment of migraine attack. Narbone MC; Abbate M; Gangemi S Neurol Sci; 2004 Oct; 25 Suppl 3():S113-8. PubMed ID: 15549517 [TBL] [Abstract][Full Text] [Related]
19. Drug treatment of migraine: Part II. Preventive therapy. Noble SL; Moore KL Am Fam Physician; 1997 Dec; 56(9):2279-86. PubMed ID: 9402813 [TBL] [Abstract][Full Text] [Related]